Legend Biotech Corporation American Depositary Shares LEGN
i
Market datapartial · fetched 2026-11-13T18:09:58.122Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:09:34.027526692Z
FundamentalsAlpha Vantage · unavailable
Legend Biotech Corporation American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 13.05 | 346.1% | 32.7% | |||
| 25Δ | 15.00 | 242.2% | 21.7% | |||
| 30Δ | 19.56 | 101.6% | 12.5% | |||
| 35Δ | 19.20 | 97.1% | 10.9% | |||
| 40Δ | 18.84 | 92.5% | 9.4% | |||
| 45Δ | 18.47 | 87.9% | 7.8% | 17.76 | 70.9% | 4.2% |
| 50Δ | 18.11 | 83.3% | 6.2% | 18.09 | 74.8% | 3.8% |
| 55Δ | 17.75 | 78.8% | 4.6% | 18.42 | 78.7% | 3.4% |
| 60Δ | 17.37 | 77.1% | 3.3% | 18.75 | 82.6% | 3.0% |
| 65Δ | 16.97 | 81.6% | 2.9% | 19.08 | 86.5% | 2.6% |
| 70Δ | 16.57 | 86.1% | 2.5% | 19.41 | 90.4% | 2.2% |
| 75Δ | 16.17 | 90.5% | 2.1% | 19.75 | 94.3% | 1.7% |
| 80Δ | 15.77 | 95.0% | 1.6% | 20.50 | 101.6% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.05
- IV
- 346.1%
- B/E move
- 32.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.00
- IV
- 242.2%
- B/E move
- 21.7%
30Δ
- Pseudo strike
- 19.56
- IV
- 101.6%
- B/E move
- 12.5%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 19.20
- IV
- 97.1%
- B/E move
- 10.9%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 18.84
- IV
- 92.5%
- B/E move
- 9.4%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 18.47
- IV
- 87.9%
- B/E move
- 7.8%
- Pseudo strike
- 17.76
- IV
- 70.9%
- B/E move
- 4.2%
50Δ
- Pseudo strike
- 18.11
- IV
- 83.3%
- B/E move
- 6.2%
- Pseudo strike
- 18.09
- IV
- 74.8%
- B/E move
- 3.8%
55Δ
- Pseudo strike
- 17.75
- IV
- 78.8%
- B/E move
- 4.6%
- Pseudo strike
- 18.42
- IV
- 78.7%
- B/E move
- 3.4%
60Δ
- Pseudo strike
- 17.37
- IV
- 77.1%
- B/E move
- 3.3%
- Pseudo strike
- 18.75
- IV
- 82.6%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 16.97
- IV
- 81.6%
- B/E move
- 2.9%
- Pseudo strike
- 19.08
- IV
- 86.5%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 16.57
- IV
- 86.1%
- B/E move
- 2.5%
- Pseudo strike
- 19.41
- IV
- 90.4%
- B/E move
- 2.2%
75Δ
- Pseudo strike
- 16.17
- IV
- 90.5%
- B/E move
- 2.1%
- Pseudo strike
- 19.75
- IV
- 94.3%
- B/E move
- 1.7%
80Δ
- Pseudo strike
- 15.77
- IV
- 95.0%
- B/E move
- 1.6%
- Pseudo strike
- 20.50
- IV
- 101.6%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 63.49% | |
| 63.22% | |
| 62.36% | |
| 71.75% | |
| 68.62% | |
| 73.90% | |
| 74.14% | |
| 85.24% | |
| 83.01% |
Biotechnology
LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs…
More →LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San…
More →LKFT
Lakefront Biotherapeutics NV (LKFT) is an innovative biopharmaceutical company focused on addressing significant unmet medical needs in oncology and infectious diseases through…
More →LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd,…
More →LXEO
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
More →